Research progress on human leucocyte antigen gene polymorphisms and drug adverse reactions

Abstract

Abstract: Drug adverse reactions which are harmful to human health have become an important public health problem. Human leucocyte antigene is the most complex gene system. Recent years, research has demonstrated that there is a strong genetic link between HLA gene and drug adverse reactions. What's more, some research achievements have also been applied broadly in clinical practice. This review covers the progress between HLA polymorphisms and drug adverse reactions and on its clinical practice

Key words: Human leucocyte antigen(HLA), Drug adverse reactions, Pharmacogenomics

CLC Number:

R968

LUO Jian-quan, ZHANG Wei. Research progress on human leucocyte antigen gene polymorphisms and drug adverse reactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 828-834.

References

[1] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies [J]. JAMA, 1998, 279(15):1200-1205.
[2] 陈旺青,张伟.撤市药物的遗传药理学[J].中国临床药理学与治疗学,2011,16(9): 1065-1071.
[3] Nakamura Y. Pharmacogenomics and drug toxicity [J]. N Engl J Med, 2008, 359(8):856-858.
[4] Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme[J]. Arch Dermatol, 1993, 129(1):92-96.
[5] Harr T, French LE.Toxic epidermal necrolysis and Stevens-Johnson syndrome [J]. Orphanet J Rare Dis ,2010,5:39-50.
[6] Chung WH, Hung S I, Hong H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome [J]. Nature, 2004, 428(6982):486.
[7] Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions[J]. Pharmacogenet Genomics, 2006, 16(4):297-306.
[8] Man CB, Kwan P, Baum L, et al. Association between HLA-B^*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese [J]. Epilepsia, 2007, 48(5):1015-1018.
[9] Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population[J]. Epilepsia, 2008, 49(12):2087-2091.
[10] Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population [J]. Epilepsia, 2010, 51(5):926-930.
[11] Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians[J]. Indian J Dermatol Venereol Leprol, 2009, 75(6):579-582.
[12] Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population[J]. Int J Dermatol, 2011, 50(2):221-224.
[13] Wang Q, Zhou JQ, Zhou LM, et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland [J]. Seizure, 2011, 20(6):446-448.
[14] Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China[J]. Epilepsy Behav, 2010, 19(3):405-408.
[15] Zhang Y, Wang J, Zhao LM, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients[J]. Eur J Clin Pharmacol, 2011, 67(9):885-887.
[16] Mccormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans [J]. N Engl J Med, 2011, 364(12):1134-1143.
[17] Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A^*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population[J]. Hum Mol Genet, 2011, 20(5):1034-1041.
[18] Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese[J]. Pharmacogenomics, 2010, 11(3):349-356.
[19] Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population[J]. Epilepsia, 2008, 49(12):2087-2091.
[20] Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Natl Acad Sci USA, 2005, 102(11):4134-4139.
[21] Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Pharmacogenomics, 2008, 9(11):1617-1622.
[22] Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs [J]. Pharmacogenet Genomics, 2008, 18(2):99-107.
[23] Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population [J]. Pharmacogenet Genomics, 2009, 19(9):704-709.
[24] Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters [J]. Pharmacogenomics J, 2006, 6(4):265-268.
[25] Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B^*1502 screening in Taiwan[J]. N Engl J Med, 2011, 364(12):1126-1133.
[26] Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J]. Lancet, 2002, 359(9308):727-732.
[27] Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir[J]. Lancet, 2002, 359(9312):1121-1122.
[28] Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant[J]. Proc Natl Acad Sci USA, 2004, 101(12):4180-4185.
[29] Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts [J]. AIDS, 2005, 19(1):97-99.
[30] Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients[J]. AIDS, 2006, 20(12):1621-1626.
[31] Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients [J]. Pharmacogenet Genomics, 2009, 19(2):139-146.
[32] Umapathy S, Pawar A, Bajpai S, et al. HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients[J]. J Pharmacol Pharmacother, 2011, 2(2):114-115.
[33] Gao S, Gui XE, Liang K, et al. HLA-Dependent Hypersensitivity Reaction to Nevirapine in Chinese Han HIV-Infected Patients [J]. AIDS Res Hum Retroviruses, 2012,28(6):540-543.
[34] Kim SH, Choi JH, Lee KW, et al. The human leucocyte antigen-DRB1^*1302-DQB1^*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticarial [J]. Clin Exp Allergy, 2005, 35(3):339-344.
[35] Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b^*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients[J]. Clin Infect Dis, 2008, 46(7):1111-1118.
[36] Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir [J]. N Engl J Med, 2008, 358(6):568-579.
[37] Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity[J]. Pharmacogenetics, 2004, 14(6):335-342.
[38] Vitezica Z G, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz [J]. AIDS, 2008, 22(4):540-541.
[39] Likanonsakul S, Rattanatham T, Feangvad S, et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients [J]. AIDS Res Ther, 2009, 6:22.
[40] Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine[J]. AIDS, 2007, 21(2):264-265.
[41] Ostapowicz G, Fontana RJ, Schiodt F V, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States [J]. Ann Intern Med, 2002, 137(12):947-954.
[42] Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment[J]. Am J Respir Crit Care Med, 2002, 166(7):916-919.
[43] Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis [J]. Pharmacogenomics J, 2008, 8(3):186-195.
[44] Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J]. Nat Genet, 2009, 41(7):816-819.
[45] O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association [J]. Gut, 2000, 47(5):717-720.
[46] Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury[J]. J Hepatol, 2010, 53(6):1049-1053.
[47] Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin [J]. J Hepatol, 1992, 15(1/2):154-161.